Medicare utilization — ABDUL ALI ABDELLATIF (M.D.)
Calendar year 2023 · data refreshed 2026-05-27
| HCPCS | Description | Services | Beneficiaries | Allowed | Payment |
|---|---|---|---|---|---|
| J3111 | Injection, romosozumab-aqqg, 1 mg | 16,800 | 11 | $0 | $132,720 |
| J0897 | Injection, denosumab, 1 mg | 8,760 | 91 | $0 | $159,076 |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 374 | 131 | $0 | $34,603 |
| 96372 | Injection of drug or substance under skin or into muscle | 250 | 98 | $0 | $2,693 |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | 217 | 122 | $0 | $25,784 |
Service volume and Medicare payment amounts do not indicate quality of care, patient outcomes, or fraud. Data reflects Medicare fee-for-service only.
Source: CMS public data · Not endorsed by CMS · Beneficiary counts under 11 are suppressed in source data ·